Milestone Pharmaceuticals announces offering of common stock, warrants

Milestone Pharmaceuticals announced that it has commenced an underwritten public offering of its common shares, and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares. All securities to be sold in the offering will be sold by the company. Milestone intends to use the net proceeds from the offering to continue the development of etripamil in its lead indication of paroxysmal supraventricular tachycardia and its subsequent indication of atrial fibrillation with rapid ventricular rate, as well as for working capital and other general corporate purposes. Piper Sandler & Co. is acting as sole bookrunning manager for the offering.